ProCE Banner Activity

ExpressPoints:
Adopting New Approaches in AL Amyloidosis: Expert Perspectives on Latest Evidence

Slideset Download
Download this short summary slideset covering management of newly diagnosed and relapsed light-chain (AL) amyloidosis.

Released: January 19, 2022

Expiration: January 18, 2023

No longer available for credit.

Share

Faculty

Ankit Kansagra

Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Vaishali Sanchorawala

Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Ankit Kansagra, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, and Janssen and consulting fees from AbbVie, Alnylam, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Takeda.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Vaishali Sanchorawala, MD, has disclosed that she has received funds for research support from Caelum, Celgene, Janssen, Karyopharm, Oncopeptide, Prothena, Sorento, and Takeda and consulting fees from Caelum, Janssen, Prothena, and Pfizer.